Vaxcyte, Inc. (PCVX) 10-Year Financial Performance & Capital Metrics

PCVX •

HealthcareBiotechnologyVaccines and Infectious Disease

AboutVaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Show more

Revenue $0
EBITDA -$899M -62.3%
Net Income -$767M -65.2%
EPS (Diluted) -5.63 -48.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -25.59% -25.4%
ROIC -24.66% -11.5%
Debt/Equity 0.04 +103.4%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 91 (top 9%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Shares diluted 11.6% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-65.25%

EPS CAGR

10Y-

5Y-

3Y-

TTM-44.44%

ROCE

10Y Avg-47.06%

5Y Avg-33.14%

3Y Avg-32.18%

Latest-29.95%

Peer Comparison

Vaccines and Infectious Disease

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
NVAXNovavax, Inc.	1.67B	10.14	3.93	64.69%	39.19%
SCNIScinai Immunotherapeutics Ltd.	3.03B	0.89	0.15		401.83%	58.65%		0.21
TNXPTonix Pharmaceuticals Holding Corp.	142.05M	13.97	-0.08	29.94%	-9.63%	-42.93%		0.04
INOInovio Pharmaceuticals, Inc.	65.34M	1.81	-0.46	-73.83%	-592.82%	-115.42%		0.17
IVVDInvivyd, Inc.	362.35M	1.69	-1.18		-119.63%	-64.32%		0.02
SPROSpero Therapeutics, Inc.	122.2M	2.17	-1.71	-53.77%	-122.56%	-165.46%		0.09
AVIRAtea Pharmaceuticals, Inc.	365.63M	4.68	-2.34			-46.56%		0.00

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	1.04M	1.23M	1.41M	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-
Gross Profit+	0	-1.04M	-1.23M	-1.41M	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-18.8%	-14.04%	100%	-	-	-	-
Operating Expenses+	17.4M	35.53M	52.92M	88.18M	103.67M	232.26M	468.04M	569.55M	923.67M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-
Selling, General & Admin	5.05M	5.39M	7.31M	14.61M	25.26M	39.81M	60.7M	92.9M	129.37M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-
Research & Development	12.79M	30.14M	45.61M	73.56M	78.41M	169.45M	332.34M	476.64M	794.31M
R&D % of Revenue	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	5.18M	0	0	0	23M	75M	0	0
Operating Income+	-17.83M	-35.53M	-54.15M	-89.58M	-103.67M	-232.26M	-468.04M	-569.55M	-923.67M
Operating Margin %	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-99.25%	-52.4%	-65.42%	-15.73%	-124.03%	-101.52%	-21.69%	-62.18%
EBITDA+	-17.21M	-34.5M	-52.92M	-88.18M	-100.21M	-222.8M	-457.87M	-553.7M	-898.82M
EBITDA Margin %	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-100.46%	-53.41%	-66.62%	-13.65%	-122.33%	-105.5%	-20.93%	-62.33%
D&A (Non-Cash Add-back)	625K	1.04M	1.23M	1.41M	3.46M	9.45M	10.17M	15.85M	24.86M
EBIT	-17.83M	-29.41M	-50.23M	-89.21M	-100.07M	-223.48M	-402.27M	-463.93M	-766.63M
Net Interest Income+	0	828K	592K	237K	337K	8.35M	62.91M	109.99M	119.72M
Interest Income	164K	903K	632K	244K	344K	8.36M	62.91M	109.99M	119.72M
Interest Expense	0	75K	40K	7K	7K	2K	0	0	0
Other Income/Expense	595K	6.05M	3.88M	364K	3.59M	8.77M	65.78M	105.62M	157.05M
Pretax Income+	-17.24M	-29.48M	-50.27M	-89.22M	-100.08M	-223.49M	-402.27M	-463.93M	-766.63M
Pretax Margin %	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	100%	100%	100%	100%	100%	100%	100%	100%	100%
Net Income+	-17.24M	-29.48M	-50.27M	-89.22M	-100.08M	-223.49M	-402.27M	-463.93M	-766.63M
Net Margin %	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	-71.05%	-70.51%	-77.46%	-12.17%	-123.31%	-80%	-15.33%	-65.25%
Net Income (Continuing)	-17.24M	-29.48M	-50.27M	-89.22M	-100.08M	-223.49M	-402.27M	-463.93M	-766.63M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-4.83	-8.12	-14.10	-2.97	-1.93	-3.44	-4.14	-3.80	-5.63
EPS Growth %	-	-68.12%	-73.65%	78.94%	35.02%	-78.24%	-20.35%	8.21%	-48.24%
EPS (Basic)	-4.84	-8.12	-14.10	-2.97	-1.93	-3.44	-4.14	-3.80	-5.63
Diluted Shares Outstanding	3.57M	3.63M	3.8M	29.55M	51.92M	64.88M	97.16M	122M	136.09M
Basic Shares Outstanding	3.56M	3.63M	3.79M	29.55M	51.92M	64.88M	97.16M	122M	136.09M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	36.35M	66.67M	61.72M	389M	256.35M	942.55M	1.1B	1.79B	1.63B
Cash & Short-Term Investments	36.14M	66.09M	58.98M	386.2M	245.97M	931.38M	1.08B	1.75B	1.56B
Cash Only	36.14M	66.09M	58.98M	386.2M	68.98M	834.66M	397.45M	387.88M	173.96M
Short-Term Investments	0	0	0	0	176.99M	96.72M	682.78M	1.36B	1.39B
Accounts Receivable	0	0	0	0	0	0	3.61M	20.66M	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	5.96M	20.11M	66.4M
Total Non-Current Assets+	3.28M	4.13M	3.98M	3.82M	67.99M	63.62M	311.96M	1.72B	1.38B
Property, Plant & Equipment	2.97M	3.41M	3.39M	3.27M	35.91M	31.65M	110.62M	270.15M	373.38M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	27.12M	26.55M	162.68M	1.39B	881.66M
Other Non-Current Assets	311K	723K	584K	550K	4.96M	5.43M	38.66M	65.68M	120.31M
Total Assets+	39.63M	70.8M	65.7M	392.83M	324.34M	1.01B	1.41B	3.51B	3B
Asset Turnover	-	-	-	-	-	-	-	-	-
Asset Growth %	-	78.65%	-7.21%	497.93%	-17.43%	210.23%	39.93%	149.4%	-14.48%
Total Current Liabilities+	4.26M	6.71M	11.05M	46.86M	28.72M	40.52M	145.34M	140.18M	205.75M
Accounts Payable	1.81M	2.83M	3.38M	29.79M	6.76M	9.79M	14.59M	48.45M	70.9M
Days Payables Outstanding	-	996.09	1K	7.74K	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	6.12M
Deferred Revenue (Current)	0	-297K	0	0	0	0	0	0	0
Other Current Liabilities	850K	2.4M	433K	298K	3.46M	1.18M	11.06M	20.55M	128.72M
Current Ratio	8.53x	9.93x	5.58x	8.30x	8.93x	23.26x	7.54x	12.75x	7.91x
Quick Ratio	8.53x	9.93x	5.58x	8.30x	8.93x	23.26x	7.54x	12.75x	7.91x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	4.43M	121.82M	161.02M	122K	11.6M	12.04M	22.11M	65.32M	111.46M
Long-Term Debt	3.76M	0	0	0	0	0	0	0	111.36M
Capital Lease Obligations	458K	161K	0	0	11.51M	12.03M	22.11M	65.22M	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	212K	121.66M	161.02M	122K	96K	9K	0	100K	100K
Total Liabilities	8.69M	128.53M	172.07M	46.98M	40.32M	52.56M	167.45M	205.5M	317.21M
Total Debt+	4.5M	458K	161K	0	16.78M	17.94M	29.22M	71.11M	117.48M
Net Debt	-31.64M	-65.63M	-58.81M	-386.2M	-52.2M	-816.72M	-368.23M	-316.77M	-56.48M
Debt / Equity	0.15x	-	-	-	0.06x	0.02x	0.02x	0.02x	0.04x
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-473.77x	-1353.83x	-12797.29x	-14810.00x	-116128.00x	-	-	-
Total Equity+	30.94M	-57.73M	-106.37M	345.84M	284.02M	953.61M	1.24B	3.31B	2.69B
Equity Growth %	-	-286.59%	-84.27%	425.12%	-17.88%	235.76%	30.08%	166.5%	-18.76%
Book Value per Share	8.68	-15.90	-28.03	11.71	5.47	14.70	12.77	27.10	19.73
Total Shareholders' Equity	30.94M	-57.73M	-106.37M	345.84M	284.02M	953.61M	1.24B	3.31B	2.69B
Common Stock	6K	6K	7K	54K	56K	82K	98K	128K	134K
Retained Earnings	-29.59M	-59.07M	-109.35M	-198.56M	-298.64M	-522.13M	-924.39M	-1.39B	-2.15B
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	-1.75M	0	0	-241K	-361K	179K	-3.87M	1.59M
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	-14.96K	-30.47M	-47.15M	-46.63M	-121.39M	-170.6M	-296.79M	-452.63M	-655.58M
Operating CF Margin %	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-203508.9%	-54.75%	1.1%	-160.34%	-40.53%	-73.97%	-52.51%	-44.84%
Net Income	-17.24K	-29.48M	-50.27M	-89.22M	-100.08M	-223.49M	-402.27M	-463.93M	-766.63M
Depreciation & Amortization	625	1.04M	1.23M	1.41M	3.46M	9.45M	10.17M	15.85M	24.86M
Stock-Based Compensation	390	749K	1.19M	5.43M	10.73M	23.65M	48.76M	84.82M	138.84M
Deferred Taxes	0	51K	0	301K	0	0	0	0	0
Other Non-Cash Items	260	-4.71M	-3.2M	179K	1.5M	7.05M	-34.77M	-34.47M	-72.56M
Working Capital Changes	1K	1.9M	3.91M	35.27M	-37.01M	12.74M	81.32M	-54.9M	19.91M
Change in Receivables	0	1.27M	868K	0	0	0	0	0	0
Change in Inventory	0	-1.19M	0	0	0	0	0	0	0
Change in Payables	0	1.27M	868K	26.1M	-12.47M	2.9M	11.22M	34.58M	19.91M
Cash from Investing+	-1.12K	-1.77M	-1.2M	-1.1M	-212.31M	74.58M	-773.31M	-2.01B	437.35M
Capital Expenditures	-1.22K	-1.77M	-1.2M	-1.16M	-6.55M	-5.84M	-67.88M	-22.43M	-13.71M
CapEx % of Revenue	-	-	-	-	-	-	-	-	-
Acquisitions	0	1K	0	50K	0	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-
Other Investing	106	1K	0	0	26K	0	0	-96.73M	-43.26M
Cash from Financing+	43.86K	62.19M	41.57M	374.87M	17.8M	861.55M	639.81M	2.45B	2.01M
Debt Issued (Net)	-188K	-283K	-278K	-61K	0	0	0	0	0
Equity Issued (Net)	0	1000K	1000K	1000K	1000K	1000K	1000K	1000K	0
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0	0
Other Financing	231.86K	128K	-655K	1.04M	3.9M	5.07M	3.77M	12.85M	2.01M
Net Change in Cash	27.78K	29.95M	-7.11M	327.22M	-316.34M	765.67M	-436.97M	-9.36M	-213.77M
Free Cash Flow+	-16.18K	-32.24M	-48.34M	-47.78M	-127.95M	-176.44M	-364.67M	-475.05M	-669.29M
FCF Margin %	-	-	-	-	-	-	-	-	-
FCF Growth %	-	-199096.79%	-49.94%	1.15%	-167.77%	-37.9%	-106.68%	-30.27%	-40.89%
FCF per Share	-0.00	-8.88	-12.74	-1.62	-2.46	-2.72	-3.75	-3.89	-4.92
FCF Conversion (FCF/Net Income)	0.00x	1.03x	0.94x	0.52x	1.21x	0.76x	0.74x	0.98x	0.86x
Interest Paid	0	0	40K	0	7K	2K	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-55.72%	-	-	-74.51%	-31.78%	-36.12%	-36.67%	-20.41%	-25.59%
Return on Invested Capital (ROIC)	-	-	-	-	-81.22%	-94.49%	-69.57%	-22.13%	-24.66%
Debt / Equity	0.15x	-	-	-	0.06x	0.02x	0.02x	0.02x	0.04x
Interest Coverage	-	-473.77x	-1353.83x	-12797.29x	-14810.00x	-116128.00x	-	-	-
FCF Conversion	0.00x	1.03x	0.94x	0.52x	1.21x	0.76x	0.74x	0.98x	0.86x

US Stock Screener

...

Vaxcyte, Inc. (PCVX) 10-Year Financial Performance & Capital Metrics

PCVX •

HealthcareBiotechnologyVaccines and Infectious Disease

Revenue $0
EBITDA -$899M -62.3%
Net Income -$767M -65.2%
EPS (Diluted) -5.63 -48.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -25.59% -25.4%
ROIC -24.66% -11.5%
Debt/Equity 0.04 +103.4%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 91 (top 9%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Shares diluted 11.6% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-65.25%

EPS CAGR

10Y-

5Y-

3Y-

TTM-44.44%

ROCE

10Y Avg-47.06%

5Y Avg-33.14%

3Y Avg-32.18%

Latest-29.95%

Peer Comparison

Vaccines and Infectious Disease

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
NVAXNovavax, Inc.	1.67B	10.14	3.93	64.69%	39.19%
SCNIScinai Immunotherapeutics Ltd.	3.03B	0.89	0.15		401.83%	58.65%		0.21
TNXPTonix Pharmaceuticals Holding Corp.	142.05M	13.97	-0.08	29.94%	-9.63%	-42.93%		0.04
INOInovio Pharmaceuticals, Inc.	65.34M	1.81	-0.46	-73.83%	-592.82%	-115.42%		0.17
IVVDInvivyd, Inc.	362.35M	1.69	-1.18		-119.63%	-64.32%		0.02
SPROSpero Therapeutics, Inc.	122.2M	2.17	-1.71	-53.77%	-122.56%	-165.46%		0.09
AVIRAtea Pharmaceuticals, Inc.	365.63M	4.68	-2.34			-46.56%		0.00

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	1.04M	1.23M	1.41M	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-
Gross Profit+	0	-1.04M	-1.23M	-1.41M	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-18.8%	-14.04%	100%	-	-	-	-
Operating Expenses+	17.4M	35.53M	52.92M	88.18M	103.67M	232.26M	468.04M	569.55M	923.67M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-
Selling, General & Admin	5.05M	5.39M	7.31M	14.61M	25.26M	39.81M	60.7M	92.9M	129.37M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-
Research & Development	12.79M	30.14M	45.61M	73.56M	78.41M	169.45M	332.34M	476.64M	794.31M
R&D % of Revenue	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	5.18M	0	0	0	23M	75M	0	0
Operating Income+	-17.83M	-35.53M	-54.15M	-89.58M	-103.67M	-232.26M	-468.04M	-569.55M	-923.67M
Operating Margin %	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-99.25%	-52.4%	-65.42%	-15.73%	-124.03%	-101.52%	-21.69%	-62.18%
EBITDA+	-17.21M	-34.5M	-52.92M	-88.18M	-100.21M	-222.8M	-457.87M	-553.7M	-898.82M
EBITDA Margin %	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-100.46%	-53.41%	-66.62%	-13.65%	-122.33%	-105.5%	-20.93%	-62.33%
D&A (Non-Cash Add-back)	625K	1.04M	1.23M	1.41M	3.46M	9.45M	10.17M	15.85M	24.86M
EBIT	-17.83M	-29.41M	-50.23M	-89.21M	-100.07M	-223.48M	-402.27M	-463.93M	-766.63M
Net Interest Income+	0	828K	592K	237K	337K	8.35M	62.91M	109.99M	119.72M
Interest Income	164K	903K	632K	244K	344K	8.36M	62.91M	109.99M	119.72M
Interest Expense	0	75K	40K	7K	7K	2K	0	0	0
Other Income/Expense	595K	6.05M	3.88M	364K	3.59M	8.77M	65.78M	105.62M	157.05M
Pretax Income+	-17.24M	-29.48M	-50.27M	-89.22M	-100.08M	-223.49M	-402.27M	-463.93M	-766.63M
Pretax Margin %	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	100%	100%	100%	100%	100%	100%	100%	100%	100%
Net Income+	-17.24M	-29.48M	-50.27M	-89.22M	-100.08M	-223.49M	-402.27M	-463.93M	-766.63M
Net Margin %	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	-71.05%	-70.51%	-77.46%	-12.17%	-123.31%	-80%	-15.33%	-65.25%
Net Income (Continuing)	-17.24M	-29.48M	-50.27M	-89.22M	-100.08M	-223.49M	-402.27M	-463.93M	-766.63M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-4.83	-8.12	-14.10	-2.97	-1.93	-3.44	-4.14	-3.80	-5.63
EPS Growth %	-	-68.12%	-73.65%	78.94%	35.02%	-78.24%	-20.35%	8.21%	-48.24%
EPS (Basic)	-4.84	-8.12	-14.10	-2.97	-1.93	-3.44	-4.14	-3.80	-5.63
Diluted Shares Outstanding	3.57M	3.63M	3.8M	29.55M	51.92M	64.88M	97.16M	122M	136.09M
Basic Shares Outstanding	3.56M	3.63M	3.79M	29.55M	51.92M	64.88M	97.16M	122M	136.09M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	36.35M	66.67M	61.72M	389M	256.35M	942.55M	1.1B	1.79B	1.63B
Cash & Short-Term Investments	36.14M	66.09M	58.98M	386.2M	245.97M	931.38M	1.08B	1.75B	1.56B
Cash Only	36.14M	66.09M	58.98M	386.2M	68.98M	834.66M	397.45M	387.88M	173.96M
Short-Term Investments	0	0	0	0	176.99M	96.72M	682.78M	1.36B	1.39B
Accounts Receivable	0	0	0	0	0	0	3.61M	20.66M	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	5.96M	20.11M	66.4M
Total Non-Current Assets+	3.28M	4.13M	3.98M	3.82M	67.99M	63.62M	311.96M	1.72B	1.38B
Property, Plant & Equipment	2.97M	3.41M	3.39M	3.27M	35.91M	31.65M	110.62M	270.15M	373.38M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	27.12M	26.55M	162.68M	1.39B	881.66M
Other Non-Current Assets	311K	723K	584K	550K	4.96M	5.43M	38.66M	65.68M	120.31M
Total Assets+	39.63M	70.8M	65.7M	392.83M	324.34M	1.01B	1.41B	3.51B	3B
Asset Turnover	-	-	-	-	-	-	-	-	-
Asset Growth %	-	78.65%	-7.21%	497.93%	-17.43%	210.23%	39.93%	149.4%	-14.48%
Total Current Liabilities+	4.26M	6.71M	11.05M	46.86M	28.72M	40.52M	145.34M	140.18M	205.75M
Accounts Payable	1.81M	2.83M	3.38M	29.79M	6.76M	9.79M	14.59M	48.45M	70.9M
Days Payables Outstanding	-	996.09	1K	7.74K	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	6.12M
Deferred Revenue (Current)	0	-297K	0	0	0	0	0	0	0
Other Current Liabilities	850K	2.4M	433K	298K	3.46M	1.18M	11.06M	20.55M	128.72M
Current Ratio	8.53x	9.93x	5.58x	8.30x	8.93x	23.26x	7.54x	12.75x	7.91x
Quick Ratio	8.53x	9.93x	5.58x	8.30x	8.93x	23.26x	7.54x	12.75x	7.91x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	4.43M	121.82M	161.02M	122K	11.6M	12.04M	22.11M	65.32M	111.46M
Long-Term Debt	3.76M	0	0	0	0	0	0	0	111.36M
Capital Lease Obligations	458K	161K	0	0	11.51M	12.03M	22.11M	65.22M	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	212K	121.66M	161.02M	122K	96K	9K	0	100K	100K
Total Liabilities	8.69M	128.53M	172.07M	46.98M	40.32M	52.56M	167.45M	205.5M	317.21M
Total Debt+	4.5M	458K	161K	0	16.78M	17.94M	29.22M	71.11M	117.48M
Net Debt	-31.64M	-65.63M	-58.81M	-386.2M	-52.2M	-816.72M	-368.23M	-316.77M	-56.48M
Debt / Equity	0.15x	-	-	-	0.06x	0.02x	0.02x	0.02x	0.04x
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-473.77x	-1353.83x	-12797.29x	-14810.00x	-116128.00x	-	-	-
Total Equity+	30.94M	-57.73M	-106.37M	345.84M	284.02M	953.61M	1.24B	3.31B	2.69B
Equity Growth %	-	-286.59%	-84.27%	425.12%	-17.88%	235.76%	30.08%	166.5%	-18.76%
Book Value per Share	8.68	-15.90	-28.03	11.71	5.47	14.70	12.77	27.10	19.73
Total Shareholders' Equity	30.94M	-57.73M	-106.37M	345.84M	284.02M	953.61M	1.24B	3.31B	2.69B
Common Stock	6K	6K	7K	54K	56K	82K	98K	128K	134K
Retained Earnings	-29.59M	-59.07M	-109.35M	-198.56M	-298.64M	-522.13M	-924.39M	-1.39B	-2.15B
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	-1.75M	0	0	-241K	-361K	179K	-3.87M	1.59M
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	-14.96K	-30.47M	-47.15M	-46.63M	-121.39M	-170.6M	-296.79M	-452.63M	-655.58M
Operating CF Margin %	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-203508.9%	-54.75%	1.1%	-160.34%	-40.53%	-73.97%	-52.51%	-44.84%
Net Income	-17.24K	-29.48M	-50.27M	-89.22M	-100.08M	-223.49M	-402.27M	-463.93M	-766.63M
Depreciation & Amortization	625	1.04M	1.23M	1.41M	3.46M	9.45M	10.17M	15.85M	24.86M
Stock-Based Compensation	390	749K	1.19M	5.43M	10.73M	23.65M	48.76M	84.82M	138.84M
Deferred Taxes	0	51K	0	301K	0	0	0	0	0
Other Non-Cash Items	260	-4.71M	-3.2M	179K	1.5M	7.05M	-34.77M	-34.47M	-72.56M
Working Capital Changes	1K	1.9M	3.91M	35.27M	-37.01M	12.74M	81.32M	-54.9M	19.91M
Change in Receivables	0	1.27M	868K	0	0	0	0	0	0
Change in Inventory	0	-1.19M	0	0	0	0	0	0	0
Change in Payables	0	1.27M	868K	26.1M	-12.47M	2.9M	11.22M	34.58M	19.91M
Cash from Investing+	-1.12K	-1.77M	-1.2M	-1.1M	-212.31M	74.58M	-773.31M	-2.01B	437.35M
Capital Expenditures	-1.22K	-1.77M	-1.2M	-1.16M	-6.55M	-5.84M	-67.88M	-22.43M	-13.71M
CapEx % of Revenue	-	-	-	-	-	-	-	-	-
Acquisitions	0	1K	0	50K	0	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-
Other Investing	106	1K	0	0	26K	0	0	-96.73M	-43.26M
Cash from Financing+	43.86K	62.19M	41.57M	374.87M	17.8M	861.55M	639.81M	2.45B	2.01M
Debt Issued (Net)	-188K	-283K	-278K	-61K	0	0	0	0	0
Equity Issued (Net)	0	1000K	1000K	1000K	1000K	1000K	1000K	1000K	0
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0	0
Other Financing	231.86K	128K	-655K	1.04M	3.9M	5.07M	3.77M	12.85M	2.01M
Net Change in Cash	27.78K	29.95M	-7.11M	327.22M	-316.34M	765.67M	-436.97M	-9.36M	-213.77M
Free Cash Flow+	-16.18K	-32.24M	-48.34M	-47.78M	-127.95M	-176.44M	-364.67M	-475.05M	-669.29M
FCF Margin %	-	-	-	-	-	-	-	-	-
FCF Growth %	-	-199096.79%	-49.94%	1.15%	-167.77%	-37.9%	-106.68%	-30.27%	-40.89%
FCF per Share	-0.00	-8.88	-12.74	-1.62	-2.46	-2.72	-3.75	-3.89	-4.92
FCF Conversion (FCF/Net Income)	0.00x	1.03x	0.94x	0.52x	1.21x	0.76x	0.74x	0.98x	0.86x
Interest Paid	0	0	40K	0	7K	2K	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-55.72%	-	-	-74.51%	-31.78%	-36.12%	-36.67%	-20.41%	-25.59%
Return on Invested Capital (ROIC)	-	-	-	-	-81.22%	-94.49%	-69.57%	-22.13%	-24.66%
Debt / Equity	0.15x	-	-	-	0.06x	0.02x	0.02x	0.02x	0.04x
Interest Coverage	-	-473.77x	-1353.83x	-12797.29x	-14810.00x	-116128.00x	-	-	-
FCF Conversion	0.00x	1.03x	0.94x	0.52x	1.21x	0.76x	0.74x	0.98x	0.86x

Vaxcyte, Inc. (PCVX) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare PCVX vs Peers

vs BNTX

vs MRNA

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Vaxcyte, Inc. (PCVX) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare PCVX vs Peers

vs BNTX

vs MRNA

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios